Status:
COMPLETED
Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborating Sponsors:
Forest Laboratories
Conditions:
Hypertension
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine if Nebivolol a) attenuates the angiotensin II (Ang II)-induced increase in oxidative stress, thereby attenuating Ang II-induced vasoconstriction; and b) atten...
Detailed Description
In 40 untreated, stage I hypertensive subjects, Investigators will measure sympathetic nerve activity (microneurography); total forearm blood flow (high-resolution ultrasonography); skeletal muscle ox...
Eligibility Criteria
Inclusion
- Stage I hypertension (140-159/90-99 mmHg)
- Men and women age 18-65
Exclusion
- Congestive heart failure or coronary artery disease
- Blood pressure averaging \>159/99 mmHg or resting heart rate \< 55 bpm
- Serum creatinine \> 1.4 mg/dL
- Asthma or chronic obstructive pulmonary diseases
- Left ventricular hypertrophy by echocardiography or ECG
- Pregnancy
- Hypersensitivity to beta blockers, microbubble contrast agents, or angiotensin
- Any history of substance abuse (other than tobacco)
- Concomitant drug treatment which raises endogenous nitric oxide levels such as nitrates or phosphodiesterase V inhibitors (Viagra, Levitra, or Cialis)
- History of symptomatic bradycardia or heart block
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT01502787
Start Date
April 1 2009
End Date
June 1 2013
Last Update
July 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Southwestern Medical Center
Dallas, Texas, United States, 75390